Hepatitis C Patients Co-infected with HIV Have Higher Risk of Liver Disease
Patients infected with both hepatitis C virus (HCV) and HIV face an 80% higher rate of decompensated cirrhosis than patients infected only with HCV, according to a retrospective cohort study led by researchers at the Perelman School of Medicine at the University of Pennsylvania.
The study, published in the March 18, 2014, issue of Annals of Internal Medicine, compares data for 4280 patients co-infected with HCV and HIV who were receiving antiretroviral therapy (ART) with data for 6079 HCV-monoinfected patients. All of the patients were HCV treatment—naïve.
Even co-infected patients who responded well to ART and maintained controlled HIV RNA levels of less than 1000 copies/mL had a 60% higher rate of serious liver disease. Rates of decompensation were also increased among co-infected patients who had advanced liver fibrosis, severe anemia, and diabetes, and among patients who were not black.
“Our results suggest that serious consideration should be given to initiating hepatitis C treatment in patients co-infected with HIV and hepatitis C—particularly among those with advanced liver fibrosis or cirrhosis—in order to try to reduce the risk of serious, potentially life-threatening complications,” said the study’s lead author.
Articles in this issue
over 11 years ago
Article
Electronic Medical Records Identify Infants at Risk of Hepatitis C Infectionover 11 years ago
Article
Treat-to-Target Approach Improves Outcome for Some New Psoriatic Arthritis PatientsNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025
- Evaluation of Pharmacist-Driven Penicillin Allergy Reconciliation
September 17th 2025
- Pharmacists Can Apply Their Expertise to the Medical Psilocybin Act
September 16th 2025
- From Curiosity to Clinical Impact: Shremo Msdi’s Path in Pharmacy Research
September 15th 2025